Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Treasury Shares (2016 - 2025)

Historic Treasury Shares for ImmunityBio (IBRX) over the last 11 years, with Q3 2025 value amounting to $163800.0.

  • ImmunityBio's Treasury Shares changed 0.0% to $163800.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $163800.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $163800.0 for FY2024, which is 0.0% changed from last year.
  • Latest data reveals that ImmunityBio reported Treasury Shares of $163800.0 as of Q3 2025, which was down 0.0% from $163800.0 recorded in Q2 2025.
  • Over the past 5 years, ImmunityBio's Treasury Shares peaked at $163800.0 during Q1 2021, and registered a low of $163800.0 during Q1 2021.
  • For the 5-year period, ImmunityBio's Treasury Shares averaged around $163800.0, with its median value being $163800.0 (2021).
  • Within the past 5 years, the most significant YoY rise in ImmunityBio's Treasury Shares was 0.0% (2021), while the steepest drop was 8514.32% (2021).
  • Quarter analysis of 5 years shows ImmunityBio's Treasury Shares stood at $163800.0 in 2021, then changed by 0.0% to $163800.0 in 2022, then changed by 0.0% to $163800.0 in 2023, then changed by 0.0% to $163800.0 in 2024, then changed by 0.0% to $163800.0 in 2025.
  • Its Treasury Shares stands at $163800.0 for Q3 2025, versus $163800.0 for Q2 2025 and $163800.0 for Q1 2025.